What is HC Wainwright’s Forecast for SRPT FY2024 Earnings?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for Sarepta Therapeutics in a research note issued to investors on Wednesday, January 15th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will post earnings of $2.68 per share for the year, up from their previous forecast of $2.30. HC Wainwright currently has a “Sell” rating and a $75.00 target price on the stock. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.17 per share. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $1.91 EPS, Q2 2025 earnings at $2.69 EPS, Q3 2025 earnings at $2.78 EPS and FY2025 earnings at $10.75 EPS.

Several other equities analysts have also recently weighed in on the company. Robert W. Baird reduced their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Guggenheim upped their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics in a report on Monday, October 21st. They set a “buy” rating and a $165.00 target price on the stock. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $178.71.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $118.00 on Friday. Sarepta Therapeutics has a 1 year low of $102.15 and a 1 year high of $173.25. The stock’s fifty day moving average price is $121.61 and its two-hundred day moving average price is $129.70. The firm has a market cap of $11.27 billion, a PE ratio of 94.40 and a beta of 0.77. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Teachers Retirement System of The State of Kentucky bought a new position in shares of Sarepta Therapeutics in the 2nd quarter valued at about $4,771,000. Simplify Asset Management Inc. raised its position in Sarepta Therapeutics by 84.6% during the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock valued at $24,105,000 after purchasing an additional 88,474 shares during the period. Geode Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after purchasing an additional 44,306 shares during the last quarter. Summit Partners Public Asset Management LLC boosted its holdings in shares of Sarepta Therapeutics by 547.9% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock worth $17,250,000 after purchasing an additional 116,800 shares during the period. Finally, Larson Financial Group LLC grew its holdings in Sarepta Therapeutics by 1,649.8% during the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock valued at $1,093,000 after purchasing an additional 8,249 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares in the company, valued at approximately $738,234. This represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.